Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
Aurora A and B are required
2024-07-19
Aurora A and B are required for the control of mitosis whereas Aurora C is mainly invoved in meiosis (Goldenson and Crispino, 2015). Interestingly, Aurora B is partnered with inner centromere protein (INCENP), survivin and Borealin to form a chromosomal passenger complex (CPC) that is critical for t
-
VEGFR inhibition using sunitinib does not result in tumor gr
2024-07-18
VEGFR2 inhibition using sunitinib does not result in tumor growth reduction or in a further decrease in vessel density in NDRG1 overexpressing glioma rendering these tumors intrinsically resistant to antiangiogenic treatment. Intrinsic resistance to antiangiogenic therapy is defined as a non-respons
-
This study demonstrates numerical alterations of creatinine
2024-07-18
This study demonstrates numerical alterations of creatinine levels potentially reflecting ongoing or even higher myocardial contraction of the LAA after successful LAAC. Creatinine is the direct breakdown product of creatine in muscle, the key metabolite for energy supply during muscular and myocard
-
The first rationally designed dual mPGES LO
2024-07-17
The first rationally designed dual mPGES-1/5-LO inhibitor was reported in 2008 and represents a structural derivative of pirinixic 327 2 - a synthetic agonist of PPARα with lipid-lowering properties (Koeberle et al., 2008b). Further α-alkyl- and α-aryl-substituted derivatives have been synthesized a
-
5823 synthesis Consistent with the observation that mutation
2024-07-17
Consistent with the observation that mutations in the redox-partner binding site of P450c17 that reverse charge from basic to acidic (R347H, R358Q) cause 17,20-lyase deficiency (Geller et al, 1997, Geller et al, 1999), at least one POR mutation that changes a residue in the FMN domain from neutral t
-
In this report the natural compound deguelin potently and
2024-07-17
In this report, the natural compound deguelin potently and dose-dependently suppressed Aurora B kinase activity in vitro, indicating that this compound is an effective Aurora B inhibitor. The docking study indicated that deguelin was docked into the ATP-binding pocket of Aurora B and formed hydropho
-
In HepG cells compound showed inhibition of total
2024-07-17
In HepG2 cells, NESS 0327 showed inhibition of total lipid syntheses with an IC of 8μM. A cell based Alamar Blue cytotoxicity assay was used in parallel to differentiate the effect on the inhibition of lipid synthesis versus potential cytotoxicity. Under identical incubation conditions, compound
-
We next sought to determine the kinase
2024-07-17
We next sought to determine the kinase responsible for IR-induced phosphorylation of 53BP1. Because the sites under investigation all lie in a consensus sequence for ATM, ATR and DNA-PK, that are all activated by IR, the involvement of each of these kinases was investigated. Preincubation of Calmida
-
Recruitment of the Rad BP mediator to chromatin
2024-07-17
Recruitment of the Rad9/53BP1 mediator to Anisodamine involves multiple pathways (Fig. 2). In unperturbed conditions, Rad9 is already bound to chromatin via interaction between its Tudor domain and methylated histone H3 at lysine 79 [82], [83], [84], [85]. This constitutive Rad9 recruitment to chro
-
Based on the extracellular domain structures we
2024-07-17
Based on the extracellular domain structures, we can infer that the dimer arrangement of GABAB receptor will undergo substantial changes upon receptor activation (Geng et al., 2013). First, agonist-stimulated closure of GABAB1 VFT would cause an upward rotation of its LB2 domain, coupled with an inw
-
Receptors containing an x y subunit
2024-07-17
Receptors containing an αx/γy subunit interface, where x=1, 2, 3, 5 and y=1–3, form a high-affinity binding site for benzodiazepines (Figure 1A), for the later developed Z-drugs of different chemotypes, and for a large number of chemically distinct research compounds 17, 18 (Box 1 for examples). For
-
br Results br Discussion AP a heterodimeric transcription fa
2024-07-17
Results Discussion AP-1, a heterodimeric transcription factor comprising various combinations of FOS, JUN, MAF, ATF, and CREB family proteins, has been known to play a pivotal role in leukocyte development for decades (Liebermann et al., 1998; Valledor et al., 1998). However, its participation
-
br Introduction Humans have consumed mushrooms
2024-07-17
Introduction Humans have consumed mushrooms for centuries because of their high nutrient content and low lipid content, as well as their excellent flavor and texture [1]. Edible mushrooms possess notable medicinal properties and bioactivities, including antitumor, antiviral, antidiabetic, and ant
-
These PrPIF are detected in untreated brain extracts
2024-07-17
These PrPIF are detected in untreated AMD-070 extracts but are consistently enriched following proteinase K (PK) treatment. The biochemical characterization of pathologic PrP has been carried out in most hereditary PrP cerebral amyloidosis associated with PrP mutations and the biochemical PrP patter
-
br Materials and methods br Results
2024-07-17
Materials and methods Results Discussion Our results revealed that LPS injection in rats impaired fear memory in the PA task. This results are in agreement with the most of previous studies reported that following acute [23,24,39,[45], [46], [47]] or chronic systemic Alisol B 23-acetate sal
15715 records 109/1048 page Previous Next First page 上5页 106107108109110 下5页 Last page